Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.43 |
| ▸ | BCL6 | P41182 | 15/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22569530 | 1.00 | FPR2 (0.43) | FPR2BCL6NCOR2 | |
| SCHEMBL26311771 | 1.00 | FPR2 (0.43) | FPR2BCL6NCOR2 | |
| SCHEMBL30595762 | 1.00 | FPR2 (0.43) | FPR2BCL6NCOR2 | |
| SCHEMBL30595766 | 1.00 | FPR2 (0.43) | FPR2BCL6NCOR2 | |
| SCHEMBL21262062 | 0.88 | BCL6 (0.46) | FPR2BCL6NCOR2 | |
| SCHEMBL22578920 | 0.85 | FPR2 (0.47) | FPR2BCL6NCOR2 | |
| SCHEMBL22578856 | 0.85 | FPR2 (0.47) | FPR2BCL6NCOR2 | |
| SCHEMBL21262182 | 0.85 | HRH4 (0.35) | FPR2 | |
| SCHEMBL22569407 | 0.81 | HDAC1 (0.35) | FPR2 | |
| SCHEMBL21262198 | 0.80 | FPR2 (0.40) | FPR2BCL6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | FPR2 4516/4885BCL6 1/4885NCOR2 61/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | FPR2 4485/4885BCL6 1/4885NCOR2 75/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | FPR2 4553/4885BCL6 1/4885NCOR2 75/4885 |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | BCL6, BCL6B, BCL3 | FPR2 4553/4885BCL6 1/4885NCOR2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.